2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

9:00AM-11:00AM: Abstract Number: 1840

How Good a Job Are We Rheumatologists Doing in Screening for Hepatitis B and C before Immuno-Suppressive/s Initiation in SLE?

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1571

How Substantive Is Heart Rate Variability As a Predictor of Anti-TNF Treatment Outcome for Inflammatory Arthritis?

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1208

How Well Do Acpas Discriminate and Predict RA in the General Population – a Study Based on 12,590 Population-Representative Swedish Twins

Epidemiology and Public Health Poster II: Pathogenesis and Treatment of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 1766

HPV Vaccination of Nzbxw/F1 Mice

Systemic Lupus Erythematosus - Animal Models Poster II

9:00AM-11:00AM: Abstract Number: 1815

Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1802

Hydroxychloroquine Level Variants and Predictors in a Connective Tissue Disease Population

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1801

Hydroxychloroquine Retinopathy: Application of the 2011 Screening Guidelines in an Academic Practice

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1806

Hydroxychloroquine Serum Levels and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1400

Hyperferritinemia and Fever in Adults

Miscellaneous Rheumatic and Inflammatory Diseases Poster Session II

9:00AM-11:00AM: Abstract Number: 1947

Hypermethylation of Treg-Specific Demethylated Regions in the Ikaros Transcription Factor Family Members, Helios and Eos, in Rheumatoid Arthritis Tregs

T cell Biology and Targets in Autoimmune Disease Poster I

9:00AM-11:00AM: Abstract Number: 1854

Identification and Characterization of microRNAs Related to the Pathogenesis of Cardiovascular Disease in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus. Role of Specific Autoantibodies

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1885

Identification and Clinical Correlations of Rare Autoantibodies in Systemic Sclerosis and Poly/Dermatomyositis Patients

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster II

9:00AM-11:00AM: Abstract Number: 1241

Identification and Validation of Diagnostic and Activity Urinary Metabolomic Biomarkers in Immune-Mediated Inflammatory Diseases

Genetics, Genomics and Proteomics Poster II

9:00AM-11:00AM: Abstract Number: 1253

Identification and Validation of Novel Putative Salivary Proteomic Biomarkers in Sjögren’s Syndrome and Different Disease Subsets

Genetics, Genomics and Proteomics Poster II

9:00AM-11:00AM: Abstract Number: 1930

Identification of a Broadly Immunogenic Prevotella Copri T Cell Epitope in Patients with Rheumatoid Arthritis

T cell Biology and Targets in Autoimmune Disease Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].